Basic Information
| LncRNA/CircRNA Name | DANCR |
| Synonyms | NA |
| Region | GRCh38_4:52712404-52720351 |
| Ensemble | ENSG00000226950 |
| Refseq | NR_024031 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP, etc. |
| Sample | breast cancer tissues including triplenegative (TNBC) type, HER2 type, Luminal A type, and Luminal B type, and normal breast tissues, BT549, MCF7, T47D, MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells??CF10A |
| Expression Pattern | up-regulated |
| Function Description | lncRNA DANCR was significantly overregulated in TNBC tissues and cell lines compared with normal breast tissues or other type of breast cancer. Knockdown of DANCR suppressed TNBC proliferation both in vitro and in vivo. Further study of underlying mechanisms demonstrated that DANCR bound with RXRA and increased its serine 49/78 phosphorylation via GSK3?, resulting in activating PIK3CA transcription, and subsequently enhanced PI3K/AKT signaling and TNBC tumorigenesis. Taken together, Our findings identified DANCR as an pro-oncogene and uncoverd a new working pattern of lncRNA to mediate TNBC tumorigenesis, which may be a potential therapeutic target for improving treatment of TNBC. |
| Pubmed ID | 30518934 |
| Year | 2018 |
| Title | LncRNA DANCR upregulates PI3K/AKT signaling through activating serine phosphorylation of RXRA |
External Links
| Links for DANCR | GenBank HGNC NONCODE |
| Links for triple negative breast cancer | OMIM COSMIC |